Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Real world" comparison favours angioplasty over thrombolytics

This article was originally published in Clinica

Executive Summary

At hospitals with angioplasty facilities, primary angioplasty should be the method of choice for treating acute myocardial infarction. This is the conclusion of the first "real world" comparison of primary angioplasty with intravenous thrombolysis based on data from 9,906 patients enrolled in two multicentre studies in Germany: the Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR). Some 87% of patients received thrombolytics and 13% angioplasty.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel